Johanna Sundin1, Lena Öhman, Magnus Simrén. 1. From the Departments of Internal Medicine and Clinical Nutrition, Institute of Medicine (Sundin, Öhman, Simrén) and Microbiology and Immunology (Sundin, Öhman), Sahlgrenska Academy at University of Gothenburg, Sweden; School of Health and Education (Öhman), University of Skövde, Sweden; and Center for Functional GI and Motility Disorders (Simrén), University of North Carolina, Chapel Hill, North Carolina.
Abstract
OBJECTIVE: During the last decade, experimental and observational studies have shown that patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) may have an altered intestinal microbial composition compared with healthy individuals. However, no uniform microbial signature has as yet been detected for either IBD or IBS. This review summarizes the current knowledge of microbial dysbiosis and its potential relationship to the pathophysiology in IBD and IBS. METHODS: A selective review was conducted to summarize the current knowledge of gut microbiota in the pathophysiology of IBD and IBS. RESULTS: Experimental and observational studies provide good evidence for intestinal microbial dysbiosis in subgroups of IBD and IBS. Still, no uniform disease pattern has been detected. This is most likely due to the heterogeneous nature of IBD and IBS, in combination with the effects of intrinsic and extrinsic factors. Such intrinsic factors include genetics, the gastrointestinal environment, and the host immune system, whereas extrinsic factors include early life diet, breastfeeding, and method of infant delivery. CONCLUSIONS: Recent and ongoing work to define microbial dysbiosis in IBD and IBS shows promise, but future well-designed studies with well-characterized study individuals are needed. It is likely that the microbial dysbiosis in IBD and IBS is dependent on the natural disease course of IBD and symptom pattern in IBS. Therefore, assessment of the entire microbiota along the gastrointestinal tract, in relationship to confounding factors, symptom fluctuations, and other pathophysiological factors, is needed for further understanding of the etiology of these common diseases.
OBJECTIVE: During the last decade, experimental and observational studies have shown that patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) may have an altered intestinal microbial composition compared with healthy individuals. However, no uniform microbial signature has as yet been detected for either IBD or IBS. This review summarizes the current knowledge of microbial dysbiosis and its potential relationship to the pathophysiology in IBD and IBS. METHODS: A selective review was conducted to summarize the current knowledge of gut microbiota in the pathophysiology of IBD and IBS. RESULTS: Experimental and observational studies provide good evidence for intestinal microbial dysbiosis in subgroups of IBD and IBS. Still, no uniform disease pattern has been detected. This is most likely due to the heterogeneous nature of IBD and IBS, in combination with the effects of intrinsic and extrinsic factors. Such intrinsic factors include genetics, the gastrointestinal environment, and the host immune system, whereas extrinsic factors include early life diet, breastfeeding, and method of infant delivery. CONCLUSIONS: Recent and ongoing work to define microbial dysbiosis in IBD and IBS shows promise, but future well-designed studies with well-characterized study individuals are needed. It is likely that the microbial dysbiosis in IBD and IBS is dependent on the natural disease course of IBD and symptom pattern in IBS. Therefore, assessment of the entire microbiota along the gastrointestinal tract, in relationship to confounding factors, symptom fluctuations, and other pathophysiological factors, is needed for further understanding of the etiology of these common diseases.
Authors: Kamaljeet Kaur; Arpit Saxena; Irina Debnath; Jacqueline L O'Brien; Nadim J Ajami; Thomas A Auchtung; Joseph F Petrosino; Alexander-Jacques Sougiannis; Sarah Depaep; Alexander Chumanevich; Phani M Gummadidala; Mayomi H Omebeyinje; Sourav Banerjee; Ioulia Chatzistamou; Paramita Chakraborty; Raja Fayad; Franklin G Berger; James A Carson; Anindya Chanda Journal: Cancer Med Date: 2018-04-06 Impact factor: 4.452
Authors: Johannes Peter; Camille Fournier; Marija Durdevic; Lukas Knoblich; Bettina Keip; Clemens Dejaco; Michael Trauner; Gabriele Moser Journal: Psychosom Med Date: 2018-10 Impact factor: 4.312